NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE American · Biotechnology · USD

AIM ImmunoTech Inc. (AIM) Stock Analysis

AIM ImmunoTech Inc. (AIM) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

Last Updated: October 21, 2026

AIM

$0.17

+$0.00 (+2.29%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AIM with… →

AIM Key Statistics

As of Oct 21, 2026
Trading
Open
$0.17
Previous Close
$0.17
Day's Range
0.17–0.17
52-Week Range
0.16–2.79
Volume
226.62K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.27
Valuation
Market Cap
$6.78M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.71
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
71.39
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.98
Financials (FY)
Revenue (FY)
$88.00K−48.24%
Net Income (FY)
−$13.96M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
39.89M
1-Year Return
−93.28%
Dividend and dates
Avg Volume
4.70M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AIM closed at $0.17, −93.28% over 1 year.

AIM ImmunoTech Inc. (AIM) has a market capitalization of $6.78M.

In fiscal 2025, AIM reported revenue of $88.00K.

AIM Stock Return by Calendar Year

AIM ImmunoTech Inc. (AIM) 10-year return: what $10,000 became

1 year
$10,000 $672
−93.28%
5 years
$10,000 $9
−99.91%
10 years
$10,000 $0.38
−99.996%

If you had invested $10,000 in AIM ImmunoTech Inc. (AIM) 10 years ago, at the close on October 21, 2016, it would have been worth $0.38 at the close on October 21, 2026: −99.996% in total, −63.90% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−84.49%
2025−94.35%
2024−54.55%
2023+41.94%
2022−66.30%
2021−48.60%
2020+231.48%
2019−93.18%
2018−48.57%
2017−49.28%
2016 (partial year)−68.06%

As of October 21, 2026.

AIM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$88.00K−$13.96M−15,861.4%
2024$170.00K−$17.32M−10,188.2%
2023$202.00K−$28.96M−14,337.6%
2022$141.00K−$19.45M−13,790.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$88.00K−$40.00K−$11.66M−$13.96M−15,861.4%
2024$170.00K$139.00K−$19.77M−$17.32M−10,188.2%
2023$202.00K$160.00K−$31.92M−$28.96M−14,337.6%
2022$141.00K$141.00K−$19.92M−$19.45M−13,790.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AIM Valuation vs Biotechnology Median

Median of 608 stocks
MetricAIMBiotechnology medianvs median
P/S ratio71.3913.305.4x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

AIM ImmunoTech Inc. (AIM) is capitalised at $6.78M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 19 employees.

The 52-week range on file runs from $0.16 to $2.79. The most recent close on file for AIM is $0.17, dated October 21, 2026. That is $0.00 (+2.29%) against the previous close. The latest close sits 6.25% above that 52-week low.

Financial Health

In fiscal 2025, AIM ImmunoTech Inc. reported revenue of $88.00K. Against the prior fiscal year total of $170.00K, that is a change of −48.24%. The same year closed with a net loss of $13.96M. Trailing earnings per share are −2.98.

Across the 4 fiscal years on file, revenue moves from $141.00K in 2022 to $88.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.71. Measured against sales, the shares trade at 71.39 times revenue. On price-to-sales that is 5.4 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.27. Annualized volatility over the trailing 10 years is 133.56%. Over the trailing twelve months the total return is −93.28%. Measured over 10 years, that is −63.90% a year compounded.

Growth & Income

No dividend is on file for AIM.

Across the complete calendar years on file, 2020 returned +231.48% and 2025 returned −94.35%. Of the 9 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is −84.49% year to date.

Peer Comparison

AIM ImmunoTech Inc. (AIM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
AIM ImmunoTech Inc. AIM $6.78M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. AIM ImmunoTech Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

Visit website →